RNAZ Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Transcode Therapeutics Inc (RNAZ) is not a strong buy for a beginner, long-term investor at this time. The lack of positive financial performance, no significant trading trends, and absence of strong technical or proprietary trading signals suggest that the stock does not present a compelling long-term investment opportunity currently.
The MACD is slightly positive but contracting, indicating weak momentum. RSI is neutral at 45.773, showing no overbought or oversold conditions. Moving averages are converging, suggesting no clear trend. The stock is trading near its pivot point of 8.971, with support at 8.047 and resistance at 9.896.
NULL identified. No recent news, no significant insider or hedge fund activity, and no recent congress trading data.
and a significant drop in EPS (-97.87% YoY). Additionally, there are no clear trading signals or positive sentiment indicators.
In Q4 2025, revenue remained at $0 with no growth. Net income improved YoY but remains significantly negative at -$15,053,321. EPS dropped drastically by -97.87% YoY to -5.82, indicating poor shareholder returns. Gross margin is 0, showing no profitability.
No analyst rating or price target data available.
